Forte Biosciences Announces Q3 Earnings Per Share of 99 Cents, Below Consensus Estimate of $1.07
"We continue to make excellent progress with FB102," said Forte Biosciences CEO Paul Wagner. "The US IND is now open and enrolment in the FB102 phase 2 celiac disease clinical trial has expanded to US sites with topline results expected in 2026. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which we reported in June, we look forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The FB102 phase 1b vitiligo clinical study is ongoing and we continue to expect topline data in 1H26. We have also begun enrolling patients in the phase 1b trial in alopecia areata and expect data from that study in 2026. With 3 key clinical trial readouts for FB102, 2026 will be a very eventful year and further highlight FB102's potential to address the significant unmet medical needs across multiple indications including celiac disease, vitiligo and alopecia areata, which represent multi-billion dollar potential market opportunities."
